Oncotarget

Reviews:

PKM2 in carcinogenesis and oncotherapy

Xia He, Suya Du, Tiantian Lei, Xiang Li, Yilong Liu, Hailian Wang, Rongsheng Tong and Yi Wang _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:110656-110670. https://doi.org/10.18632/oncotarget.22529

Metrics: PDF 1086 views  |   HTML 1746 views  |   ?  


Abstract

Xia He1,*, Suya Du2,*, Tiantian Lei2,*, Xiang Li2,*, Yilong Liu3, Hailian Wang4, Rongsheng Tong1 and Yi Wang1

1Department of Pharmacy, Sichuan Academy of Medical Science & Sichuan Provincial People’s Hospital, Chengdu, Sichuan 610072, China

2School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan 610054, China

3Department of Pharmacy, The People’s Hospital of Leshan, Leshan, Sichuan 614000, China

4Institute of Organ Transplantation, Sichuan Academy of Medical Science & Sichuan Provincial People’s Hospital, Chengdu, Sichuan 610072, China

*These authors have contributed equally to this work

Correspondence to:

Yi Wang, email: w_yi@yahoo.com

Rongsheng Tong, email: tongrs@126.com

Keywords: PKM2; Warburg effect; aerobic glycolysis; carcinogenesis; oncotherapy

Received: August 16, 2017     Accepted: October 28, 2017     Published: November 20, 2017

ABSTRACT

Tumor cell metabolism is characterized by abundant glucose consumption and aerobic glycolysis. And pyruvate kinase M2 (PKM2) plays a decisive role in glycolysis, significantly contributing to the Warburg effect, tumor growth, angiogenesis, cell division, metastasis and apoptosis. To date, researchers have unraveled the potential of pyruvate kinase M2 as an antitumor target, which suggests a new orientation for oncotherapy. Herein, we focus on the role of pyruvate kinase M2 in tumor cell development and its function as a potential new therapeutic target for tumor treatment. Besides, research actuality on pyruvate kinase M2-dependent glycometabolism and signaling pathway in tumors is also summarized, providing valuable suggestions for further study in this field.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 22529